The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1268-1274

  Gabrielson, Marike ^a   Tina, Elisabet ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cell cycle arrest; Cytotoxicity; Human epidermal growth factor receptor 2 positive breast cancer; SLC25A43; Viability

Indexed keywords

CARRIER PROTEIN; CYTOSTATIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; KI 67 ANTIGEN; MITOCHONDRIAL TRANSPORT PROTEIN; PACLITAXEL; SLC25A43 PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL LINE; CELL PROLIFERATION; CELL STRAIN BT 474; CELL STRAIN MCF 7; CELL STRAIN MCF10A; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; MITOCHONDRIA; PACLITAXEL; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEINS;

EID: 84874716161     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2247     Document Type: Article

References (47)

1. Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460, 1998.
2. Abal M, Andreu JM and Barasoain I: Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3: 193-203, 2003.
3. Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: molecular advances and pharmacologic devel¬opments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229, 2004.
4. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
5. Frankel A, Buckman R and Kerbel RS: Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 57: 2388-2393, 1997.
6. Sparano JA: Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 1: 32-42, 2000.
7. Cersosimo RJ and Hong WK: Epirubicin: a review of the phar¬macology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4: 425-439, 1986.
8. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclo¬phosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23: 7483-7490, 2005.
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
10. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16: 2651-2658, 1998.
11. Baselga J, Albanell J, Molina MA and Arribas J: Mechanism of action of trastuzumab and scientific update. Semin Oncol 28: 4-11, 2001.
12. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70, 1999.
13. Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM and McMahon M: Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 24: 10868-10881, 2004.
14. Mullany LK, Nelsen CJ, Hanse EA, et al: Akt-mediated liver growth promotes induction of cyclin E through a novel trans¬lational mechanism and a p21-mediated cell cycle arrest. J Biol Chem 282: 21244-21252, 2007.
15. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL: Herceptin-induced inhibition of phosphati¬dylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132 4141, 2002.
16. Montemurro F and Aglietta M: Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer 6: 77-80, 2005.
17. Montemurro F, Valabrega G and Aglietta M: Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 5: 81-96, 2004.
18. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676 3685, 2005.
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005.
20. Finkel T and Hwang PM: The Krebs cycle meets the cell cycle: mitochondria and the G1-S transition. Proc Natl Acad Sci USA 106: 11825-11826, 2009.
21. Detmer SA and Chan DC: Functions and dysfunctions of mito¬chondrial dynamics. Nat Rev Mol Cell Biol 8: 870-879, 2007.
22. Schieke SM, McCoy JP Jr. and Finkel T: Coordination of mito¬chondrial bioenergetics with G1 phase cell cycle progression. Cell Cycle 7: 1782-1787, 2008.
23. Mandal S, Guptan P, Owusu-Ansah E and Banerjee U: Mitochondrial regulation of cell cycle progression during devel¬opment as revealed by the tenured mutation in Drosophila. Dev Cell 9: 843-854, 2005.
24. Jones RG, Plas DR, Kubek S, et al: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293, 2005.
25. Gwinn DM, Shackelford DB, Egan DF, et al: AMPK phosphory¬lation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226, 2008.
26. Owusu-Ansah E, Yavari A, Mandal S and Banerjee U: Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint. Nat Genet 40: 356-361, 2008.
27. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
28. Tina E, Malakkaran Lindqvist B, Gabrielson M, Lubovac Z, Wegman P and Wingren S: The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell prolif¬eration in HER2-positive breast tumors. BMC Cancer 12: 350, 2012.
29. Tina E, Prenkert M, Hoglund M, Paul C and Tidefelt U: Topoisomerase IIa expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C. Oncol Rep 22: 1527-1531, 2009.
30. Lantz E, Cunningham I and Higa GM: Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health 1: 155-171, 2010.
31. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329, 2009.
32. Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA and Sutherland RL: Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 630: 189-205, 2008.
33. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
34. Tudor G, Aguilera A, Halverson DO, Laing ND and Sausville EA: Susceptibility to drug-induced apoptosis correlates with differ¬ential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ 7: 574-586, 2000.
35. Sunters A, Madureira PA, Pomeranz KM, et al: Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 66: 212-220, 2006.
36. Kutuk O and Letai A: Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68: 7985-7994, 2008.
37. Zhou M, Zhao Y, Ding Y, et al: Warburg effect in chemo¬sensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer 9: 33, 2010.
38. Gogvadze V, Orrenius S and Zhivotovsky B: Mitochondria as targets for chemotherapy. Apoptosis 14: 624-640, 2009.
39. Tan M, Jing T, Lan KH, et al: Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9: 993-1004, 2002.
40. Lane HA, Motoyama AB, Beuvink I and Hynes NE: Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibi¬tion of HER2 receptor signaling. Ann Oncol 12 (Suppl 1): S21-S22, 2001.
41. Nahta R, Takahashi T, Ueno NT, Hung MC and Esteva FJ: P27(kip1) down-regulation is associated with trastuzumab resis¬tance in breast cancer cells. Cancer Res 64: 3981-3986, 2004.
42. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE and Dowsett M: Apoptosis and proliferation as predictors of chemo¬therapy response in patients with breast carcinoma. Cancer 89: 2145-2152, 2000.
43. MacGrogan G, Mauriac L, Durand M, et al: Primary chemo¬therapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458-1465, 1996.
44. Colleoni M, Viale G, Zahrieh D, et al: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10: 6622-6628, 2004.
45. Rozan S, Vincent-Salomon A, Zafrani B, et al: No significant predictive value of c-erbB-2 or p53 expression regarding sensi¬tivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27-33, 1998.
46. Rau B, Sturm I, Lage H, et al: Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21: 3391-3401, 2003.
47. Pohl G, Rudas M, Taucher S, et al: Expression of cell cycle regu¬latory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78: 97-103, 2003.